At the news
? BULLISHIMPACT 6/10 8-K filed Jul 22, 2026 at 07:00 ET
NRX Pharmaceuticals' subsidiary NRX Defense Systems received a letter from DARPA indicating its SPARC-TMS clinical trial proposal was selected for negotiation of a potential award. The Phase 2/3 trial combines robotic-enabled TMS with NRX-101 (which has FDA Breakthrough Therapy Designation) for depression remission. This is a non-binding selection, no award has been made and definitive terms remain subject to negotiation, but it represents a significant validation of the company's technology platform by a major government agency.
- NRX Defense Systems (NRXD) received a letter from DARPA selecting its SPARC-TMS proposal for negotiation of a potential award.
- The SPARC-TMS trial is a Phase 2/3 trial combining robotic-enabled Transcranial Magnetic Stimulation with NRX-101 (D-cycloserine/lurasidone) for depression remission.
- NRX-101 previously received FDA Breakthrough Therapy Designation.
- The trial protocol is FDA-approved and posted on clinicaltrials.gov (NCT07227103).
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access